Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 6/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.68 |
| ▸ | PKM | P14618 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | RECQL | P46063 | 3/20 | 0.68 |
| ▸ | SNCA | P37840 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | APEX1 | P27695 | 2/20 | 0.68 |
| ▸ | ALPL | P05186 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | APP | P05067 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | RAD52 | P43351 | 2/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.68 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meciadanol SCHEMBL13784973 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL29929029 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL30049526 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL862417 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL790768 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL29929253 | 1.00 | BACE1 (0.68) | BACE1KDM4EPKMGAAMEN1 | |
| SCHEMBL862107 | 0.90 | MMP2 (0.59) | BACE1KDM4EPKMGAAMEN1 | |
| SCHEMBL862196 | 0.89 | MMP2 (0.61) | BACE1KDM4EPKMGAAMEN1 | |
| SCHEMBL862370 | 0.89 | MMP2 (0.61) | BACE1KDM4EPKMGAAMEN1 | |
| Meciadanol SCHEMBL27830923 | 0.88 | DYRK1A (0.73) | BACE1KDM4EPKMGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-11324685-B2 | Process for treating hair | KAO GERMANY GMBH (DE) | 2022-05-10 | — | — | US | claimed |
| EP-3463276-B1 | PROCESS FOR TREATING HAIR | KAO GERMANY GMBH (DE) | 2022-03-02 | — | — | EP | claimed |
| WO-2021158575-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| WO-2021158573-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2021-08-12 | — | — | WO | claimed |
| US-20200405797-A1 | TRANSMUCOSAL DELIVERY DEVICE AND METHOD OF MANUFACTURING SAME | NANOSTRIPS, INC. (US) | 2020-12-31 | — | — | US | claimed |
| WO-2020136240-A1 | POLYPHENOL-PEPTIDE CONJUGATES FOR NUCLEAR-TARGETED DELIVERY | Universität Wien (AT) | 2020-07-02 | — | — | WO | claimed |
| EP-2559434-A2 | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist | Nicolaou, Mike (US) | 2013-02-20 | — | — | EP | claimed |
| CN-102458555-A | Rejuvenating coronary artery by improving blood flow with the help of insertion of nano-balls (encapsulated nanoparticles) containing therapeutic agents by non implantable device for tissues and thereby providing in tissue release to address the requ | CONCEPT MEDICAL INC | 2012-05-16 | — | — | CN | claimed |
| CN-101516407-B | improving arginase levels/activity | MARS INC | 2012-03-21 | — | — | CN | claimed |
| US-20100144718-A1 | TREATMENT OF DISEASES MODULATED BY A H4 RECEPTOR AGONIST | NICOLAOU MICHALIS | 2010-06-10 | — | — | US | claimed |
| EP-2170317-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | Nicolaou, Mike (US) | 2010-04-07 | — | — | EP | claimed |
| CN-101516407-A | Improving arginase levels/activity | MARS INC (US) | 2009-08-26 | — | — | CN | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| US-20080207530-A1 | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs | NICOLAOU MICHALIS | 2008-08-28 | — | — | US | claimed |
| WO-2008100539-A1 | TREATMENT OF COPD, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES AND OTHER GASTROINTESTINAL CONDITIONS AND DISORDERS AMELIORATED BY PROPER HISTAMINE MANAGEMENT USING A COMBINATION OF HISTIDINE DECARBOXYLASE INHIBITORS, LRA DRUGS, ANTI-H1 AND/OR ANTI-H2 DRUGS | NICOLAOU MICHALIS (US) | 2008-08-21 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | BACE1 465/4885KDM4E 4637/4885PKM 3166/4885 |
| US-11324685-B2 | Process for treating hair | TYR, TET2, COXFA4L2 | BACE1 2375/4885KDM4E 292/4885PKM 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.